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Portal hypertension is a common and serious condition in children. 
The management of portal hypertension in children has undergone 
significant change with the advent of liver transplantation, progress 
in interventional radiology and advances in the medical and 
endoscopic management of variceal haemorrhage.[1,2] We report on 
our experience with shunt surgery over a 12-year period and provide 
a brief overview of literature.
Methods
Ethics approval was obtained from the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. M170647). All patients 
that underwent shunt surgery at Chris Hani Baragwanath Academic 
Hospital, Charlotte Maxeke Johannesburg Academic Hospital, Wits 
Donald Gordon Medical Centre and MediClinic Sandton between 
2005 and 2017 were included in the study. All candidates for inclusion 
were identified by a review of the databases of the Department 
of Paediatric Surgery at the University of the Witwatersrand. 
Demographic data, medical data, and data on surgical technique and 
outcome were collected by means of a retrospective record review. 
Descriptive statistics were calculated using Microsoft Excel.
Results
A total of 14 shunt procedures were performed on 12 patients between 
2005 and 2017. Unfortunately, complete records on shunt surgery 
performed within the academic public hospitals in Johannesburg 
were only found for 2 patients. The remainder of cases performed 
within public hospitals were untraceable due to data gaps resulting 
from poor record keeping. The Department of Paediatric Surgery has 
instituted a system for electronic record management with the aim 
to address this problem. Half of all patients (6/12) were male. The 
median age (range) at surgery was 6.5 (1 - 18) years. Gastrointestinal 
haemorrhage that was not amenable to endoscopic control was the 
primary indication for surgery in 83% (10/12) of cases. The majority 
of patients in our series demonstrated features of hypersplenism. 
Portal vein thrombosis was the most common cause of portal 
hypertension, accounting for 92% (11/12) of cases. Two-thirds (8/12) 
of patients had some identifiable risk factor for portal vein thrombosis. 
Seven patients underwent a distal splenorenal shunt (DSRS), 
4 underwent a meso-portal bypass procedure (MRB, Rex shunt), 
and 1 had a mesocaval bypass. All patients received post-operative 
thromboprophylaxis in the form of aspirin, except for 2 patients 
with known protein C deficiency who were initially given a low-
molecular-weight heparin (enoxaparin) instead. A single patient that 
initially underwent a MRB procedure experienced shunt thrombosis 
at 3 years post surgery. This patient subsequently underwent a 
DSRS.  We experienced 2 cases of shunt stenosis due to anastomotic 
stricture. One such stricture occurred in a patient that underwent 
mesocaval bypass and required revision of the anastomosis at 1 year 
post surgery. This patient demised from systemic sepsis 6 weeks 
after relook surgery, and was the only mortality in our series. The 
second patient with an anastomotic stricture is currently awaiting 
radiological venoplasty. Both anastomotic strictures occurred in 
patients with known protein C deficiency. These data are summarised 
in Tables 1, 2 and 3 and Fig. 1 shows the spleen size v. platelet count 
by means of a scatter plot.
Discussion
Normal portal pressure ranges from 0 to 10 mmHg and is usually 
slightly higher than the pressure in the inferior vena cava.[3] The 
pressure gradient between the portal and caval systems, or the hepatic 
venous pressure gradient (HVPG), is normally <4 mmHg. It is low 
owing to the high compliance and low resistance of the portal vein, 
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hepatic sinusoids and hepatic veins. As such, portal hypertension 
(PHT) is defined as either: (i) a hepatic venous pressure gradient 
>5 mm Hg, or (ii) hepatic venous wedge pressure >10 mmHg. 
Clinically, portal hypertension becomes relevant at a HVPG of >10 
mmHg, as this is the threshold gradient associated with variceal 
haemorrhage in adults.[4] Typically, portal hypertension is defined by 
its clinical manifestations: (i) variceal gastrointestinal haemorrhage, 
(ii) splenomegaly and/or hypersplenism, (iii) portal hypertensive 
gastropathy, (iv) ascites, (v) portopulmonary disorders, (vi) growth 
abnormalities, or (vii) encephalopathy or learning disorders.[2,4] 
Although age at presentation and the specific history of presentation 
are variable and dependent on the underlying disease process, 
up to two-thirds of all patients with portal hypertension present 
with a history or features of upper gastrointestinal haemorrhage 
and splenomegaly. This constellation of symptoms is considered 
pathognomonic for portal hypertension.[4] 
Portal hypertension can be classified into two categories, namely 
(i) portal hypertension caused by primary liver pathology with 
associated fibrosis, or (ii) portal hypertension owing to primary 
vascular abnormalities.[3] Both groups can be further subdivided 
according to the nature of the underlying disease process. Regardless 
of aetiology, the underlying pathophysiology ultimately involves 
(i) an increase in resistance to flow through the portal tract, (ii) an 
increase in flow through the portal tract, or (iii) a combination of 
both.[2,3] Understanding the aetiology of portal hypertension  impacts 
significantly on the surgical strategies available for its management 
and potential complications.[2,3] 
Pre-surgical management of portal hypertension in children is 
focussed on the management of variceal haemorrhage and is largely 
based on adult trials.[4] Management may be thought of in terms of 
primary prophylaxis, secondary prophylaxis, and emergency treatment 
of variceal bleeding. All management options involve surveillance 
endoscopy, administration of beta–blockers and/or somatostatin 
analogues, and endoscopic band ligation or sclerotherapy.[4]
Up to 15% of children with portal hypertension ultimately require 
shunt surgery. While shunt surgery may be classified as elective or 
emergent, improvements in the endoscopic management of variceal 
bleeding means that emergency shunt surgery to control upper 
gastrointestinal bleeding is now a rare occurrence.[2,4] In the modern 
era, shunt surgery is reserved for patients with extrahepatic portal 
hypertension in whom the procedure may be curative, and those 
with sufficient hepatic reserve where a risk benefit analysis favours 
shunt surgery over liver transplantation. More specific indications for 
elective shunt surgery are presented in Table 4.[1,3,5]
Table 1. Demographic data and risk factors
Patient 
no.
Age 
(years) Gender Risk Factor
1 11 F None
2 15 M Neonatal umbilical catheter
3 8 F None
4 13 F Neonatal umbilical catheter
5 5 M Neonatal umbilical catheter
6 1 F Previous liver transplant
7 10 M Cystic fibrosis
8 1 F Protein C deficiency
9 2 F None
10 7 M Protein C deficiency
11 6 F None
12 5 M Neonatal umbilical catheter
F = female; M = male.
Table 2. Patient characteristics
Patient 
no.
Spleen size
(cm) INR
Platelet 
count
(x 109/L)
Presenting 
symptoms
1 11 1.1 30 GI haemorrhage
2 15 1 90 GI haemorrhage
3 8 1.2 86 GI haemorrhage
4 13 1 77 GI haemorrhage
5 5 1 98 GI haemorrhage
6 1 1.2 68 Ascites
7 10 1.4 33 GI haemorrhage
8 1 1 40 GI haemorrhage
9 2 1 90 GI haemorrhage
10 7 1.1 82 GI haemorrhage
11 6 1.2 78 GI haemorrhage
12 5 1 198 GI haemorrhage
INR = international normalised ratio; GI = gastrointestinal.
Table 3. Diagnosis, surgical procedure, and outcome
Patient no. Diagnosis Procedure Outcome
1 PVT Distal splenorenal Patent till present
2 PVT Mesoportal Thrombosed, DSRS 3 years post initial surgery
3 PVT Mesoportal Patent till present
4 PVT Mesoportal Patent till present
5 PVT Distal splenorenal Patent till present
6 PVT Distal splenorenal Patent till present
7 Cystic fibrosis Distal splenorenal Patent till present
8 PVT Mesocaval Anastomotic stenosis, distal anastomosis revised 1 year 
after primary surgery, demised from sepsis 6 weeks 
post revision
9 PVT Distal splenorenal Patent till present
10 PVT Distal splenorenal Anastomotic stenosis, awaiting venoplasty
11 PVT Mesoportal Patent till lost to follow up 2 years post surgery
12 PVT Distal splenorenal Patent till present
PVT = portal vein thrombosis; DSRS = distal splenorenal shunt.
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Shunt surgery may be thought of as physiological or non-physiological. 
The only true physiological shunt is the meso-portal bypass shunt 
(MRB, Rex shunt) in which an obstructed portal vein is bypassed to 
restore normal hepatopetal flow.[3,6,7] Non-physiological shunts result 
in the diversion of blood from the mesenteric and portal systems to 
the systemic circulation. Non-physiological shunts can be further 
divided into selective and non-selective shunt groups, with the non-
selective group being further divided into total and partial shunts. 
Total non-selective shunts, such as the portocaval, mesocaval and 
proximal splenorenal shunts, create direct communication between 
the portal and systemic circulation. Depending on the specific 
technique, these shunts can create a full diversion of flow with a 
consequent fall in portal pressure. While this significantly reduces 
the risk of bleeding from varices, it is also associated with a marked 
increase in the risk of encephalopathy.[2-4] In contrast, partial non-
selective portosystemic shunts (such as the Sarfeh shunt) maintain 
some portal flow and are thus associated with lower rates of post-
operative encephalopathy. This benefit comes at the cost of higher 
rates of shunt thrombosis and recurrent variceal bleeding.
Selective shunts such as the DSRS (also known as the Dean Warren 
shunt) are intended to only decompress the compartment associated 
with variceal bleeding. In this way these shunts maintain some 
portopetal flow and avoid the encephalopathy associated with non-
selective shunts. With time, this selectivity is lost and selective shunts 
progressively centralise.[2,3,6,7]
Prehepatic portal hypertension is the most common cause of 
portal hypertension in children. In most cases this is due to idiopathic 
portal vein thrombosis, with <25% of patients reported to have 
some history of umbilical vein catheterisation, trauma, previous 
surgery or peritonitis.[4] The MRB is an example of a portoportal 
shunt and was first described in 1992 as a technique to treat portal 
vein thrombosis post liver transplantation.[7]  This procedure utilises 
a graft patch between the superior mesenteric vein and the left 
portal vein at the level of the Rex recesses to bypass portal vein 
obstruction and restore flow to the liver.[1,3,7] The MRB restores 
portal venous flow, thus restoring normal physiology. In this way, it 
resolves portal hypertension in patients with isolated extrahepatic 
portal vein obstruction (EHPVO) and, as such, is the only curative 
surgical shunt. Successful MRB facilitates the reversal of the effects 
of portal hypertension including: (i) restoration of hepatopetal 
flow; (ii) resolution of portosystemic collaterals; (iii) reversal of 
hepatopulmonary syndrome; (iv) resolution of hypersplenism; (v) 
improved neurocognitive function; and (vi) decreased risk of focal 
nodular hyperplasia in the liver.[7]
Shunt thrombosis and anastomotic stricture are significant 
post-operative complications, though patency rates of 97% and 
thrombosis rates of <5% are reported within the international 
literature.[1-3] Outcomes are better in patients undergoing Rex 
bypass earlier in the disease process and current recommendations 
are for children with EHPVO to undergo MRB prior to the onset of 
portal hypertension.[3]
With advances in microsurgical techniques, and through the 
experience gained in vascular and transplant surgery, shunt surgery 
(including MRB) is now successfully performed in children as 
small as 4 kg.[3] Prerequisites for a successful Rex procedure are (i) 
the absence of intrinsic liver pathology, (ii) a patent intrahepatic 
portal tree, and (iii) the presence of a suitable conduit (usually the 
internal jugular vein (IJV)). The choice of conduit impacts patency 
rate, with IJV grafts having the highest patency rate and cadaveric 
iliac vein grafts the lowest patency rates.[3] Shunt patency must 
be checked postoperatively within the first week, using Doppler 
ultrasonography, and post-operative thromboprophylaxis with dual 
antiplatelet therapy (aspirin and dipyridamole) is recommended for 
3 - 6 months.[2,3]  
The basic work-up of patients requiring shunt surgery involves: 
(i) an assessment of the cause of portal hypertension; (ii) an 
assessment of the patient’s hepatic reserve; and (iii) the anatomy of 
the portal venous tree.[1-3,6,7] Correct delineation of the anatomy of 
the portal tree is critical to surgical planning and can be achieved 
through Doppler ultrasonography, contrasted computed tomography, 
magnetic resonance venography or, most definitively, through 
formal portal venography. Imaging must demonstrate the anatomy 
(including length and separating distance) and patency of the portal 
vein, superior mesenteric vein, splenic vein, left renal vein, inferior 
vena cava, and the left portal vein.[1-3,6,7] Doppler ultrasonography 
may also be used to assess the patency and calibre of the internal 
jugular veins if they are considered as conduits for bypass.[3] In cases 
of primary liver pathology with associated fibrosis, the pre-operative 
workup should include a percutaneous liver biopsy.[3] Hepatic reserve 
is measured by various criteria, the most common being the Child’s 
Pugh or Paediatric End Stage Liver Disease (PELD) scoring systems. 
Both systems estimate hepatic reserve by scoring patients on hepatic 
synthetic function as measured by albumin, International Normalised 
Ratio (INR), and total bilirubin levels. Preoperative assessment of 
coagulation profiles is essential in nontransplant vascular surgery 
such as shunt surgery. Given that coagulopathy is a risk for intra- and 
post-operative haemorrhage and shunt thrombosis, patients with a 
history of venous thrombosis (portal or other) must be thoroughly 
screened to identify those with genetic hypercoagulability.[3]
Alternatives to shunt procedures include devascularisation 
procedures such as the Sugiura procedure.[2-4] All devascularisation 
procedures involve splenectomy and in the era of endoscopy and 
liver transplantation these procedures are considered obsolete. In 
selected cases of severe hypersplenism, splenectomy or splenic artery 
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Fig. 1. Spleen size v. platelet count.
Table 4. Indications for shunt surgery in portal hypertension
Uncontrolled bleeding from oesophageal varices*
Bleeding from gastric or ectopic varices
Hypersplenism or massive splenomegaly
Isolated extrahepatic portal vein obstruction 
Lack of access to endoscopy
Symptomatic biliary obstruction due to choledochal varices
Neurological impairment
Patient choice
*That is, no response to at least 2 sessions of endoscopic treatment.
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embolisation has been described. Splenic artery embolisation 
reduces flow into the portal system, thereby decreasing portal 
pressures and bleeding from varices, although this is a temporary 
achievement.[2-4]
Splenic artery embolisation becomes relevant in instances of 
thrombosis or stenosis of DSRS and persistent hypersplenism. 
Adverse consequences of splenic artery embolisation or splenectomy 
include post-splenectomy sepsis and intra-abdominal adhesions 
that increase risks associated with future shunt surgery.[2-4] As such, 
surgical or radiological splenectomy are considered last resorts in 
children with portal hypertension.[2] Children with intrinsic liver 
disease and insufficient hepatic reserve should not be considered 
candidates for shunt surgery. In such cases, the rate of complications 
of shunt surgery prevail over the potential benefits and these children 
should rather be considered for primary liver transplantation.[3]
Conclusion
The management of portal hypertension in children has undergone 
significant improvements with advances in the available medical, 
endoscopic, surgical and radiological interventions for the 
treatment of portal hypertension and its complications. These 
advances include: (i) beta-blockers in the pre-primary and primary 
prophylaxis of variceal haemorrhage; (ii) endoscopic band ligation 
and sclerotherapy in the setting of acute variceal haemorrhage and 
as secondary prophylaxis; (iii) advances in liver transplantation 
techniques increasing feasibility of the procedure in children; and 
(iv) advances in interventional endovascular radiological procedures. 
Collectively, these advances have significantly decreased the need 
for emergency and elective shunt and non-shunt surgery in the 
management of portal hypertension. This said, shunt surgery remains 
relevant in patients with non-cirrhotic portal hypertension, in 
whom shunt surgery may be curative, and in those with sufficient 
hepatic reserve who fail to respond to more conservative treatment 
options as a bridge to transplantation. The choice of shunt surgery 
depends on the underlying pathology, overall health of the patient 
(including a measure of hepatic reserve), patient choice, and the 
available technical expertise. With advances in surgical technique, 
shunt surgery is a feasible option in children with well compensated 
cirrhosis or EHPVO regardless of their age or size. Shunt surgery 
prevents GI bleeding, corrects splenomegaly and hypersplenism, 
portal biliopathy, ascites and can alleviate growth retardation.[2-4,6]
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